UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Proportion of subjects in the experienced cohort with SVR12

Time frame: Follow up Week 12

Proportion of subjects in each cohort who achieve HCV RNA <LOQ TD/TND

Time frame: On-treatment Weeks: 1, 2, 4, 6, 8, and 12; post treatment Weeks 4 (SVR4), 8 (SVR8) and 24 (SVR24)

Proportion of subjects in each cohort who achieve HCV RNA <LOQ TND

Time frame: On-treatment Weeks: 1, 2, 4, 6, 8, and 12; post treatment weeks 4, 8, 12 and 24

Safety measured by frequency of serious AEs (SAEs) and discontinuations due to adverse events (AEs) through the end of treatment in each cohort

Time frame: Up to post treatment week 4 (±7 days)

Proportion of anemia defined as Hg <10 g/dL on-treatment and Hg ≥10 g/dL at baseline , in each cohort

Time frame: Up to post treatment week 4 (±7 days)

Rates of selected grade 3-4 lab abnormalities (hematologic and liver function) in each cohort

Time frame: Up to post treatment week 4 (±7 days)

Proportion of subjects in each cohort achieving SVR12 associated with HCV geno subtype 1a vs 1b

Time frame: Post treatment week 12